$4.72
-0.12-2.48%
At Close: -
$4.71
-0.0100-0.21%
After Hours: 8:09 AM EDT
15 minutes delayed
Capricor Therapeutics
CAPRNASDAQ
Capricor Therapeutics (NASDAQ:CAPR) Stock, Analyst Ratings, Price Targets, Predictions
Capricor Therapeutics Inc has a consensus price target of $21.75, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co. on July 2, 2024, May 17, 2024, and May 14, 2024. With an average price target of $31.33 between HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co., there's an implied 565.25% upside for Capricor Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
Cantor Fitzgerald
Ladenburg Thalmann
1calculated from analyst ratings
Analyst Ratings for Capricor Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | Buy Now | 749.26% | HC Wainwright & Co. | Joseph Pantginis | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 197.24% | Oppenheimer | Leland Gershell | → $14 | Initiates | → Outperform | Get Alert |
| 05/14/2024 | Buy Now | 749.26% | HC Wainwright & Co. | Joseph Pantginis | → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 69.85% | Cantor Fitzgerald | Kristen Kluska | → $8 | Reiterates | Overweight → Overweight | Get Alert |
| 05/14/2024 | Buy Now | 430.79% | Ladenburg Thalmann | Aydin Huseynov | $24 → $25 | Maintains | Buy | Get Alert |
| 04/25/2024 | Buy Now | 749.26% | HC Wainwright & Co. | Joseph Pantginis | → $40 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 749.26% | HC Wainwright & Co. | Joseph Pantginis | — | Reiterates | Buy → Buy | Get Alert |
| 01/05/2024 | Buy Now | 69.85% | Cantor Fitzgerald | Kristen Kluska | → $8 | Initiates | → Overweight | Get Alert |
| 10/04/2023 | Buy Now | 749.26% | HC Wainwright & Co. | Joseph Pantginis | $18 → $40 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 282.17% | HC Wainwright & Co. | Joseph Pantginis | → $18 | Reiterates | Buy → Buy | Get Alert |
| 03/16/2023 | Buy Now | 282.17% | HC Wainwright & Co. | Joseph Pantginis | → $18 | Reiterates | → Buy | Get Alert |
| 10/26/2022 | Buy Now | 218.47% | Ladenburg Thalmann | Aydin Huseynov | → $15 | Initiates | → Buy | Get Alert |
| 01/31/2022 | Buy Now | 282.17% | HC Wainwright & Co. | Joseph Pantginis | $14 → $18 | Maintains | Buy | Get Alert |
| 10/11/2021 | Buy Now | 197.24% | HC Wainwright & Co. | Joseph Pantginis | $9 → $14 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Capricor Therapeutics (CAPR) stock?
The latest price target for Capricor Therapeutics (NASDAQ:CAPR) was reported by HC Wainwright & Co. on July 2, 2024. The analyst firm set a price target for $40.00 expecting CAPR to rise to within 12 months (a possible 749.26% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Capricor Therapeutics (CAPR)?
The latest analyst rating for Capricor Therapeutics (NASDAQ:CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics reiterated their buy rating.
When was the last upgrade for Capricor Therapeutics (CAPR)?
There is no last upgrade for Capricor Therapeutics
When was the last downgrade for Capricor Therapeutics (CAPR)?
There is no last downgrade for Capricor Therapeutics.
When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.
Is the Analyst Rating Capricor Therapeutics (CAPR) correct?
While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a reiterated with a price target of $40.00 to $40.00. The current price Capricor Therapeutics (CAPR) is trading at is $4.71, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.